Genes are one of the most powerful windows into the biology of autism, and it has been 19 estimated that perhaps a thousand or more genes may confer risk. However, less than 20 100 genes are currently viewed as having robust enough evidence to be considered 21 true "autism genes". Massive genetic studies are underway to produce data to 22 implicate additional genes, but this approach, although necessary, is costly and slow-23 moving. Here, we approach autism gene discovery as a machine learning problem, 24 rather than a genetic association problem, and use genome-scale data as predictors for 25 identifying further genes that have similar properties in the feature space compared to 26 established autism risk genes. This approach, which we call forecASD, integrates 27 spatiotemporal gene expression, heterogeneous network data, and previous gene-level 28 predictors of autism association to yield a single score that represents each gene's 29 likelihood of being involved in the etiology of autism. We demonstrate that forecASD 30 has substantially increased sensitivity and specificity compared to previous gene-level 31 predictors of autism association, including genetic-based measures such as TADA. On 32 an independent test set, consisting of newly-released pilot data from the SPARK 33 Genomics Consortium, we show that forecASD best predicts which genes will have an 34 excess of likely gene disrupting (LGD) mutations. Using forecASD results, we show 35 which molecular pathways are currently under-represented in the autism literature and 36 likely represent under-appreciated biological mechanisms of autism. Finally, the larger 37 importance of this work is that by enumerating the genes that are most likely involved in 38 the pathogenesis of autism, we have an opportunity to consider what molecular 39 research in autism might look like in a post-gene discovery era. 40 41 42 43 44
Introduction enrichment analyses are provided in Supplemental Table 2 . Statistical analyses 168 described in results and discussion were all performed in R 15 using either glm() or 169 fisher.test(). Pathway-summarized haploinsufficiency (pLI: probability of loss-of-function 170 intolerance 16 ) was calculated by counting the proportion of genes in a Reactome 171 pathway satisfying pLI>0.9. Gene-wise and pathway-level comparisons with ASD 172 case/control brain gene expression data were performed using frontal cortex RNA-seq 173 summary statistics from Gandal et al. 17 . Our preliminary tests showed that both SFARI 174 HC and forecASD showed the highest agreement with expression data from the frontal 175 cortex. The goal of our approach was to create a gene-wise score that indexes the level of 215 evidence for involvement in ASD using both systems biology (i.e., network and 216 transcriptional data) and genetic features. An initial forecASD systems biology model 217 was built (forecASD:sys) using only BrainSpan expression and the STRING database 218 shortest paths matrices as features. This model was trained on the high confidence set 219 of 76 SFARI genes scoring 1 or 2 (SFARI HC genes), with negative training labels 220 assigned to 1,000 background genes that were not listed in the SFARI gene database. As an initial test of performance, we scored genes hit by coding de novo mutations To facilitate a comparison with manually curated gene prioritizations, we scored all 239 genes in the SFARI gene database using forecASD, forecASD:sys, and the most 240 comprehensive TADA feature in the forecASD model. Shown in figure 2C , the forecASD 241 model ranks SFARI genes scoring 3, 4, 5 and syndromic-only as significantly more 242 autism-related than TADA (P: 7.7x10 -4 , 4.7x10 -11 , 2.3x10 -4 , 7.7x10 -6 ). The forecASD 243 model also significantly outperforms the limited forecASD:sys model in gene categories 244 2, 3, and 4 (P: 8.4x10 -5 , 2.15x10 -7 , 4.0x10 -5 , respectively). In all cases, forecASD 245 prioritizes SFARI genes as well, or better than TADA and forecASD:sys. 246 gene sets and characteristics well known to be overrepresented in autism genes (Fig. 249 2D). We first performed several overrepresentation tests and found that genes receiving 250 forecASD scores in the top decile (1,787 genes, referred to as forecASD genes) had a 251 significant overlap with known targets of CHD8 (P < 1 x 10 -16 ), FMRP (P < 1 x 10 -16 ), 252 and the full SFARI gene database (P < 1 x 10 -16 ). We next performed a series of 253 functional enrichment tests, comparing forecASD genes to randomly sampled sets of 254 background genes. Text mining in PubMed showed that forecASD genes were 255 significantly overrepresented in abstracts which mention autism (P < 0.001). Given the 256 established role of autism genes early in fetal development, we next tested and found 257 that forecASD genes showed significantly higher rates of coexpression across all 258 regions of the fetal brain (P < 0.001). Lastly, forecASD genes were shown to have 259 significantly enriched rates of interaction in the STRING database (P < 0.001).
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We next tested the ability of these scores to discriminate both high confidence (Fig. 3A ) 262 and trending ( Fig. 3B ) autism genes from negative background genes. High confidence 263 autism genes (SFARI HC) are defined as scoring 1 or 2 in SFARI Gene, with trending 264 autism genes scoring 3. Importantly, the negative set of non-autism genes was sampled 265 to have the same background mutation rate as the autism genes (P>0.1 by the 266 Kolmogorov-Smirnov test). In both comparisons, forecASD showed the highest level of 267 performance of all methods tested (AUC=0.97 for SFARI 1+2 and AUC=0.82 for SFARI 268 Gene score 3; Fig. 3 ). Furthermore, while the SFARI HC genes were used to train the 269 forecASD model, only "out of bag" predictions were used as the forecASD score for those genes, i.e., only those trees where the gene was not included in the bootstrap 271 sample voted for the class of the gene. None of the trending autism genes (Fig. 3B ) 272 were used to train forecASD, and consequently they provide an unbiased estimate of 273 performance. Table 2 ). To highlight 299 new biological themes that forecASD detects but that are not clear from the list of 300 SFARI HC genes, we prioritized pathways based on differential enrichment (Fig. 4 ).
301 Figure 4A highlights pathways that were represented in SFARI HC genes, but that 302 showed significantly greater enrichment in forecASD genes. Figure 4B shows a 303 sampling of the most significant forecASD pathways not represented by any SFARI HC 304 gene, thus highlighting under-appreciated mechanisms in autism.
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While SFARI HC genes show a strong bias toward genes with high pLI (P<0.001,
307
Fisher's exact test; Fig. 5A ), forecASD is significantly less biased (P<0.001, Fisher's 308 exact test). We also discovered a significant relationship between pLI and differential 309 expression (DE) t-statistics in case/control brain gene expression studies 17 (beta=-0.13, 310 t-statistic-4.3, P=1.9x10 -5 , Fig. 5B ), potentially exposing a form of bias in current gene 311 discovery approaches that leads to under-ascertainment of ASD risk genes with low pLI 312 and upregulation in ASD cases. We also found a significant interaction between 313 forecASD and pLI (F=54.1, P=3.9x10 -24 ) such that the pLI-expression relationship exists 314 among forecASD genes (beta=-0.24, t=-2.6, P=0.009; Fig. 5D ) but is absent in non-315 forecASD genes (beta=0.004, t=0.1, P=0.91; Fig. 5C ).
Lastly, forecASD genes were loaded into the STRING network and clustered using a enriched for Potassium signaling (P=1.8x10 -49 ) which lacked significant overlap with 434 SFARI HC genes. In addition to this cluster, there were also seven others lacking Two Random Forest classifiers, one using BrainSpan gene expression and the other using the STRING network as predictors, are trained to discriminate high confidence autism genes (SFARI HC, scores 1 and 2) from a set of 1,000 genes drawn randomly from those not listed at all in the SFARI Gene database. Predictions are then made on the remainder of the genome, and these are combined with the out-of-bag (OOB) estimates from the training process to yield a prediction for each gene in the genome. A subsequent classifier is then trained using the output of these two RFs and previously published autism gene scores as predictive features, and again predictions are made on the remainder of the genome, with OOB predictions being used for those genes in the training set. The RF vote proportion for class "autism gene" is then the final forecASD score.
Figure 2 -Prioritization of de novo likely gene-disrupting mutations and enrichment of gene sets in forecASD.
Training a limited model, forecASD:sys, using brain gene expression and interaction data shows optimal prioritization of de novo LGDs when combined with a genetic measure of autism association (a). Building the full forecASD model, we test all features for their informativeness, finding that the STRING score is primary (b). Using the three mentioned scores, we assess their genome-wide ranking of SFARI genes at all levels, and find that the full forecASD model at least ties, and often significantly outperforms TADA and forecASD:sys in the prioritization of SFARI genes (c). As an initial assessment of forecASD prioritized genes, we find the top decile of genes ranked by forecASD (1787 genes) shows enrichment typical of classical autism genes (d). 451 452 453 Figure 3 -Comparison of forecASD with prior models of autism gene prioritization. To compare forecASD with competitors, we evaluate performance by each methods' ability to prioritize SFARI genes and genes which were subject to recurrent de novo loss-of-function or missense mutations. Starting with SFARI genes scoring 1 or 2 as a positive set and size-matched random background genes as the negative set, forecASD out-of-bag estimates showed superior classification over all methods (a). In a fully unbiased test, forecASD estimates also showed superior classification of trending SFARI genes (score: 3) over all other methods (b). Using two sequencing cohorts which no methods draw information from, the top decile of forecASD genes (1787 genes) shows the greatest overlap with genes containing recurrent de novo loss-of-function and missense mutations (c). When excluding genes in the SFARI gene database, forecASD still shows superior prioritization of genes accumulating de novo mutations (d). When testing the top-decile genes according to forecASD for Reactome pathway enrichment, pathways emerged that were represented, but not enriched in the SFARI HC list (a). Other pathways were highly enriched in forecASD genes that were not represented at all in the SFARI HC list, even though they have associated literature suggesting a role in autism (b). forecASD is more sensitive than SFARI HC to pathways that are differentially regulated in the brains of individuals with autism, particularly in ASD-upregulated pathways (c), but also in downregulated pathways (d). Using the top decile of TADA -log10 FDR genes showed similar sensitivity to SFARI HC (not shown), suggesting that rare variant approaches may be less sensitive in implicating genes found through gene expression studies.
Figure 5 -Relationship between pLI and ASD-specific up-and down-regulation of brain gene expression.
SFARI HC is strongly biased toward genes with high pLI (a), while forecASD is significantly less biased. We found a significant relationship between pLI and differential expression (DE) in the brains of autism cases (b), such that low pLI genes tend toward upregulation in cases, while high pLI genes tend to be downregulated. We also observed a significant interaction between forecASD and pLI such that the observed pLI-DE trend (b) is absent in non-forecASD genes (c), and present and significant among forecASD genes (d). We propose that the presence of the pLI-DE trend is a hallmark of ASD risk genes, and an optimal ASD gene prioritization method will concentrate the trend among risk genes and remove it from non-risk genes. Notably, no threshold of TADA (tested to the 50 th percentile) was able to remove the trend from the non-prioritized genes, suggesting the persistence of residual risk genes that were not selected. 
